CENTOGENE is a data-driven rare disease company – unlocking the complexities of patients’ biology to empower innovative solutions for the global rare disease community.
By working together with patients, physicians, and partners, we are leveraging our multi-pronged method to diagnose, understand, and treat rare diseases.
WHAT WE DO
Diagnose - CENTOGENE’s Clinical Dx footprint reaches far beyond our German roots. Having diagnosed over 2,500 rare diseases across 100 countries alongside a network of over 20,000 physicians, we are the indisputable partner for rare disease diagnostics.
Understand – Over the past 15+ years, CENTOGENE has generated data-driven insights based on our Dx business. By performing in-house research to understand the genetic causes of rare diseases, we have discovered unique links between metabolic and neurological diseases.
Treat - To date, we have collaborated with over 40 biotech and pharmaceutical partners covering over 45 different rare diseases and hold several patents on biomarkers. CENTOGENE is currently aggressively pursuing three priority diseases – Gaucher disease, Niemann-Pick type C, and genetic Parkinson’s, while simultaneously creating a multiomic pool of data to drive to exponentially unlock the links between diseases to accelerate cures.
Brands: NEW CentoXome®, CentoMetabolic®, CentoGenome®, NGS Panels, Bio/Databank
NEW CentoXome® – Turning Years Into Days